Moo Suk Park Republic of Korea

Dear, APSR fellows and colleagues My name is Moo Suk, Park MD., PhD. I was bone in Seoul, South Korea. I graduated Yonsei University College of Medicine, and trained in Severance Hospital in Seoul during internship, residency, and fellowship. I have been working at Yonsei University College of Medicine, and Severance Hospital as an instructor, assistant professor, and associate professor period. Now I am a professor in Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital. I am a Head of APSR ILD assembly. My research areas and topics are interstitial lung diseases, lung transplantation, and critical care. These areas are closely associated with each other and my concern is started in ILD and progress to end-stage care of ILD including intensive care and lung transplantation. In South Korea, Korea ILD study group under The Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) made nation-wide ILD cohort at 2008 and new IPF registry (Korea IPF cohort, KICO) at 2018. I act as a key researcher and development of nation-wide IPF cohort and registry. And I was a corresponding author in a study for Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis.
Job Title
Professor
Faculty / Department / Division
Department of Internal Medicine / Pulmonary and Critical Care Medicine
Institution / Organisation
Yonsei University College of Medicine, Severance Hospital

20 November 2026, Friday

Time Session
09:30
11:00
Moo Suk Park Chairperson Republic of Korea
Noorul Afidza Muhammad Chairperson Malaysia
  • Ganesh Raghu Speaker United States
  • Jin Woo Song Speaker Republic of Korea
    Interstitial lung abnormalities (ILAs) are chest CT findings suggestive of interstitial lung disease (ILD) in people without a clinical diagnosis of ILD. With lung cancer screening and the wide use of CT, they are increasingly encountered in respiratory practice. The 2025 American Thoracic Society (ATS) clinical statement updated the 2020 Fleischner Society definition: ILA is now defined as bilateral, nondependent ground-glass or reticular abnormalities, lung distortion, traction bronchiectasis, or honeycombing involving at least 5% of a lung zone, without the requirement that the findings be incidental, and with high-risk groups such as familial pulmonary fibrosis and connective tissue disease included. A working definition separates ILA from ILD on the basis of symptoms, physiology, imaging, and pathology. ILA is found in about 3–10% of older adults and 4–17% of smokers. Risk factors include older age, male sex, smoking, occupational and environmental exposures, the MUC5B promoter variant, short telomeres, and a family history of pulmonary fibrosis. ILA is associated with respiratory symptoms, reduced exercise capacity, lung cancer, complications of cancer treatment and surgery, acute respiratory distress syndrome, and all-cause mortality. About half of ILAs progress radiologically, and subpleural fibrotic ILA, reticulation, and traction bronchiectasis carry the highest risk of progression and death. Based on 11 questions, the ATS statement suggests systematic assessment of ILA on lung cancer screening CT, baseline CT for adults with connective tissue disease at risk of ILD and for first-degree relatives older than 50 years in familial pulmonary fibrosis, assessment of symptoms and lung function at baseline, and serial CT timed by risk; it suggests against lung biopsy and routine MUC5B or telomere testing. Risk reduction, including smoking cessation and exposure remediation, is recommended throughout. No pharmacological treatment is currently recommended for ILA, but prevention trials with better-tolerated antifibrotics, such as DROP-FPF with nerandomilast, have begun. This lecture reviews the definition, epidemiology, clinical significance, risk assessment, and management of ILA, with data from Korean cohorts.
  • Yasuhiko Nishioka Speaker Japan
  • Q&A
Ballroom 4, Lower Ground Floor

21 November 2026, Saturday

Time Session
11:00
12:30
14:00
15:30
Amila Rathnapala Chairperson Sri Lanka
Gin Tsen Chai Chairperson Singapore
  • Marissa O'Callaghan Speaker Ireland
    Pulmonary alveolar proteinosis (PAP) is a rare but treatable cause of respiratory impairment that presents important diagnostic and therapeutic challenges. Using a case-based approach, this presentation will explore when to suspect PAP, how to confirm the diagnosis and distinguish its underlying causes, and when to consider treatment. It will highlight the roles of bronchoalveolar lavage and GM-CSF autoantibody testing, alongside practical approaches to assessing disease severity and progression. Established and emerging treatments, including whole-lung lavage and inhaled GM-CSF, will be discussed. Attendees will gain a practical framework for recognising PAP, initiating appropriate investigations and identifying patients who would benefit from specialist referral.
  • Moo Suk Park Speaker Republic of Korea
  • Q&A
Ballroom 3, Lower Ground Floor